Recorded device evidence

RAPIDVUE HCG TEST (K102175): indications, design and recorded evidence

The acquired K102175 file contains product-specific indications and users, design and operating principle, performance evidence actually described sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-07. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 2 selected decisions under primary code JHI. 2 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

No quartiles are displayed: this complete-year cohort has fewer than 20 valid pairs.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K102175 ↗ · this pageRAPIDVUE HCG TEST2010-08-02 → 2010-08-2523Special
K262299 ↗Instant-View® hCG Combo II Cassette Test2026-07-07 → 2026-09-2277Traditional
K241919 ↗Innovita HCG Pregnancy Rapid Combo Test2024-07-01 → 2024-08-0232Traditional
K203272 ↗Alltest Pregnancy Rapid Combo Test Cassette2020-11-06 → 2022-01-31451Traditional
K172322 ↗Atellica IM Total hCG (ThCG)2017-08-01 → 2018-03-29240Traditional

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 0 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K102175 · PDF page 1 ↗ Source 2

The         RapidVue          hCG      test       is an           immunoassay
                                                                                                                                                                                            intended    for   the        qualitative      detection     of       human
                                                                                                                                                                                            Chorionic      Gonadotropin           (hCG)            in urine    for    theintended
                                                                                                                                                                                            early  detection        of         pregnancy.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K102175 · PDF page 2 ↗ Source 3

The       RapidVue          hCG      test       uses     a monoclonal
                                                                                                                                                                                                                                                                                        antibody     specific     to     the      beta       subunit      of   hCG         in a
                                                                                                                                                                                                                                                                                        single-step      technology    to       accurately  detect          hCG.
                                                                                                                                                                                                                                                                                        The      Dipstick         is dipped         in urine.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Performance evidence actually described

K102175 · PDF page 3 ↗ Source 4

Numerous       analytical        studies     were          undertaken       to     document     the      performance
               characteristics        and      the        substantial      equivalence    of   the           RapidVue      hOG      test    to     the
                predicate      device.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {}.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK102175 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categoryRAPIDVUE HCG TEST [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantQuidel Corporation [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeJHI [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2010-08-25 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeSpecial [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2010-08-02 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Performance evidence actually described — what differs in our product?

    The source labels this section as performance data. Determine which described evidence is bench, software, biological or clinical from the actual narrative and original tables; the section label alone does not settle that distinction or prescribe your testing.

    Useful evidence: The cited narrative and full tables, underlying protocols/results and a reviewed comparison with the proposed product.

Work packages and dependencies

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[1768] · record 0c4b4851e368fa728974197326247b22f2a44f6af00414b473db2e7f3e6d39e1
  • [5] Complete results array / fda-decision-context:K102175 · record whole dataset partition

FDA 510(k) summary — K102175 ↗

Tue, 07 Sep 2010 12:15:11 GMT · retrieved 2026-10-07

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot 71deda16e68bd8b5e59ceb1c64b752c261713687b24eba01af6c54a4b6047462

  • [2] PDF page 1 · record 2d55f64b2cc1ea42c81e5ffd32eadcbd4bc86822b20651e31378255815ceae73
  • [3] PDF page 2 · record f1f7c4695684bf0e2ce48d3b46c27fe750311f2f3f10879b6a0ec35efab88133
  • [4] PDF page 3 · record 06ef313f1bcb644aa83664605daedca02c8cb4f0a7110999d7f228240c8eb98b

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services